However, its tumor‐shrinkage efficacy is limited, with many patients developing resistance after prolonged treatment.[32, 33] In this study, we investigated whether targeting CLTB or SH3KBP1 synergizes with sorafenib to inhibit HCC progression in PDX models. Here, CLTB is linked to neoplasm.